变构调节
化学
效应器
细胞内
糖酵解
结合
瓦博格效应
生物化学
细胞生物学
癌细胞
共价键
激活剂(遗传学)
细胞毒性
细胞生长
癌症研究
细胞
细胞毒性T细胞
酶
厌氧糖酵解
流出
多重耐药
四聚体
生物
药物输送
生物物理学
调解人
肿瘤细胞
小分子
肽
细胞培养
新陈代谢
作者
Xiaoding Jiang,Eric M. Lynch,Congcong Lyu,Crystal N. Wilson,Lauren E. Salay,Hayden T. Hess,Scott N. Lyons,Shuangyu Luo,Shuangyu Luo,Gibae Kim,Hsin‐Ru Chan,5,Lauren G. Zacharias,Thomas P. Mathews,Yi‐Chih Lin,Bradley A. Webb,Justin M. Kollman,Xiaolu A. Cambronne,Ku‐Lung Hsu
标识
DOI:10.1038/s41589-026-02289-9
摘要
Glycolysis fuels vital cellular functions, and its dysregulation has been implicated in cancer, neurodegeneration, antibiotic resistance and diabetes. The glycolytic dependency of cancer, known as the Warburg effect, represents a key vulnerability for development of targeted anticancer agents; however, the development of such agents remains challenging owing to metabolic heterogeneity and resistance. Here we developed a covalent phosphofructokinase-1 liver type (PFKL) activator that couples glycolytic activation with delivery of a cytotoxic carnitine palmitoyltransferase 2 (CPT2)-targeting payload to cancer cells in vitro and in vivo. The electrophile–drug conjugate site-specifically and proteome-wide selectively modifies K677 in the allosteric effector site to stabilize the R-state tetramer of PFKL, while concomitantly releasing a CPT2-selective inhibitor to destabilize cell metabolism. The delivery mechanism of electrophile–drug conjugates is analogous to that of antibody–drug conjugates, but differentiated by their selective covalent targeting of intracellular proteins. An electrophile–drug conjugate covalently activates PFKL through K677 engagement and releases a selective CPT2-targeting payload. This strategy exploits metabolic vulnerabilities to suppress tumor growth in vitro and in vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI